Cargando…

Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab

See related Letter

Detalles Bibliográficos
Autores principales:	Fujii, Koki, Takahashi, Hidenori, Hayakawa, Nami, Iwasaki, Yoshinobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788443/ https://www.ncbi.nlm.nih.gov/pubmed/33437491 http://dx.doi.org/10.1002/rcr2.708

Ejemplares similares

Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2020)

Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Requena, Gema, et al.
Publicado: (2021)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
por: Kay, Dana, et al.
Publicado: (2018)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
por: Lachance, Madeleine, et al.
Publicado: (2022)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
por: Li, Lisha, et al.
Publicado: (2021)

Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis
por: Alves, José Mario, et al.
Publicado: (2021)

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022)

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome
por: Roufosse, Florence, et al.
Publicado: (2023)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
por: Cook, Alistair, et al.
Publicado: (2021)

Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
por: Vantaggiato, Lorenza, et al.
Publicado: (2022)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023)

Eyelid Swelling and Subconjunctival Infiltration as Ophthalmic Manifestations in a Child with Idiopathic Hypereosinophilic Syndrome
por: Kim, Jeong-Ah, et al.
Publicado: (2018)

Reply to “Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era”
por: Lang, Claudia Cécile Valérie, et al.
Publicado: (2021)

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
por: Reiter, Andreas, et al.
Publicado: (2022)

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
por: Roufosse, Florence, et al.
Publicado: (2020)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

PB2229: A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME
por: Ogbogu, Princess, et al.
Publicado: (2023)

Correspondence: Reply to ‘Phantom phonon localization in relaxors’
por: Manley, Michael E., et al.
Publicado: (2017)

Correspondence: Reply to: ‘Correspondence: Variations in ocean heat uptake during the surface warming hiatus'
por: Liu, Wei, et al.
Publicado: (2016)

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
por: Menzella, Francesco, et al.
Publicado: (2015)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
por: Isoyama, Shoko, et al.
Publicado: (2022)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
por: Caminati, Marco, et al.
Publicado: (2023)

Reply to the correspondence to the “Guideline for acute therapy and management of anaphylaxis”
por: Ring, Johannes
Publicado: (2015)

Correspondence: Reply to ‘On the bonding in ligand-protected gold clusters’
por: Xu, Wen Wu, et al.
Publicado: (2017)

Correspondence: Reply to ‘Chimpanzee helping is real, not a byproduct’
por: Jensen, Keith, et al.
Publicado: (2018)

Correspondence: Reply to ‘DNA shape is insufficient to explain binding'
por: Kasinathan, Sivakanthan, et al.
Publicado: (2017)

Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α – benralizumab
por: Kosałka-Węgiel, Joanna, et al.
Publicado: (2021)

Disseminated intravascular coagulation as an unusual feature of hypereosinophilic syndrome
por: Hu, Rong-Hua, et al.
Publicado: (2019)

Correspondence and Reply of Dr. W. Mitchell
Publicado: (1892)

Correspondence: Reply to ‘The experimental requirements for a photon thermal diode’
por: Chen, Zhen, et al.
Publicado: (2017)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Correspondence (reply): The application conditions of false discovery rate control
por: Zhang, Hongbin, et al.
Publicado: (2022)

Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Publicado: (2021)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s81qtmrjp8objgrudvgjs96d4s